Rilzabrutinib

Rilzabrutinib
Clinical data
Trade names	Wayrilz
Other names	PRN-1008
AHFS/Drugs.com	Wayrilz
License data	US DailyMed: Rilzabrutinib;
Routes of; administration	By mouth
Drug class	Antineoplastic
ATC code	None;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name (E)-2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile;
CAS Number	1575591-66-0;
PubChem CID	73388818;
DrugBank	DB17709;
ChemSpider	58893525;
UNII	NWN58M4F5T;
KEGG	D11873;
ChEMBL	ChEMBL3702854;
Chemical and physical data
Formula	C36H40FN9O3
Molar mass	665.774 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(/C=C(\C#N)/C(=O)N1CCC[C@H](C1)N2C3=NC=NC(=C3C(=N2)C4=C(C=C(C=C4)OC5=CC=CC=C5)F)N)N6CCN(CC6)C7COC7;
	InChI InChI=1S/C36H40FN9O3/c1-36(2,45-15-13-43(14-16-45)26-21-48-22-26)18-24(19-38)35(47)44-12-6-7-25(20-44)46-34-31(33(39)40-23-41-34)32(42-46)29-11-10-28(17-30(29)37)49-27-8-4-3-5-9-27/h3-5,8-11,17-18,23,25-26H,6-7,12-16,20-22H2,1-2H3,(H2,39,40,41)/b24-18+/t25-/m1/s1; Key:LCFFREMLXLZNHE-GBOLQPHISA-N;

Rilzabrutinib, sold under the brand name Wayrilz, is an anti-cancer medication used for the treatment of immune thrombocytopenia. Rilzabrutinib is a tyrosine kinase inhibitor. It is taken by mouth.

Rilzabrutinib may increase the risk of serious infections (including bacterial, viral, or fungal). The most common side effects include diarrhea, nausea, headache, abdominal pain, and COVID-19.

Rilzabrutinib was approved for medical use in the United States in August 2025.